🇺🇸 FDA
Pipeline program

Linaclotide 290 micrograms

LIN-MD-31

Phase 3 small_molecule completed

Quick answer

Linaclotide 290 micrograms for Irritable Bowel Syndrome Characterized by Constipation is a Phase 3 program (small_molecule) at IRONWOOD PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).

Program details

Company
IRONWOOD PHARMACEUTICALS INC
Indication
Irritable Bowel Syndrome Characterized by Constipation
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials